Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 3—March 2025
Research Letter
Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment
Figure

Figure. Flowchart of MDR TB isolates identified in France during 2008–2022 included in an evaluation of high-dose isoniazid in MDR TB treatment. DST, drug susceptibility testing; MDR TB, multidrug-resistant tuberculosis; SCR, short-course regimen.
Page created: January 07, 2025
Page updated: February 21, 2025
Page reviewed: February 21, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.